Internal link ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome March 17, 2021 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference March 02, 2021 at 09:30 PM UTC
Internal link ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results February 25, 2021 at 12:00 PM UTC
Internal link ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome February 16, 2021 at 09:30 PM UTC
Internal link ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10 January 07, 2021 at 12:00 PM UTC
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index December 24, 2018 at 12:00 PM UTC
Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10 December 18, 2018 at 03:27 PM UTC
Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10 December 17, 2018 at 04:52 PM UTC
Internal link ProQR Announces Strategic Changes to the Management Team and Key New Hires December 13, 2018 at 12:00 PM UTC
Internal link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10 December 10, 2018 at 12:00 PM UTC
Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients December 04, 2018 at 12:00 PM UTC
Internal link ProQR to Present at the Evercore ISI HealthConX Conference November 20, 2018 at 12:00 PM UTC
Internal link ProQR Announces Financial Results for the Third Quarter of 2018 November 07, 2018 at 12:00 PM UTC
Internal link ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference October 31, 2018 at 11:00 AM UTC
Internal link ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten für die Augenheilkunde von Ionis Pharmaceuticals October 30, 2018 at 10:15 PM UTC
Internal link ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals October 29, 2018 at 11:33 AM UTC
Internal link ProQR to Present at the Chardan Genetic Medicines Conference October 02, 2018 at 11:00 AM UTC
Internal link ProQR Announces Presentations at the OTS Annual Meeting September 24, 2018 at 11:00 AM UTC
Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares September 11, 2018 at 08:01 PM UTC
Internal link ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares September 07, 2018 at 08:21 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares September 05, 2018 at 08:01 PM UTC
Internal link ProQR annonce des résultats intermédiaires positifs pour un essai clinique de phase 1/2 du QR-110 chez des patients souffrant de ACL10 et prévoit de commencer un essai pivot de phase 2/3 September 05, 2018 at 09:46 AM UTC
Internal link ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial September 05, 2018 at 08:00 AM UTC
Internal link ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th August 15, 2018 at 11:00 AM UTC
Internal link ProQR Announces Financial Results for the Second Quarter of 2018 August 08, 2018 at 11:00 AM UTC